Jubilant Pharmova Q1 Results FY27: Date, Revenue Estimates, Key Catalysts and Share Price Target

Jubilant Pharmova Q1 Results FY27 is coming into focus as investors position ahead of the July-August 2026 results season, with Jubilant Pharmova shares trading at Rs.975 against a market capitalisation of Rs.15,494 Cr and a price-to-earnings multiple of 39.0. As an industrials and capital goods name on the NSE and BSE, Jubilant Pharmova enters the Jubilant Pharmova Q1 Results FY27 print with the Street watching revenue momentum, margin trajectory and management commentary on FY27 guidance.

This Jubilant Pharmova Q1 Results FY27 preview is built on a trailing-growth framework applied to the company’s Q1 FY26 base of Rs.1,913 Cr revenue and Rs.102 Cr net profit, using the most recent year-on-year growth signal from Q4 FY26. This Q1 prediction is a Uniresearch trailing-growth projection, not a formal analyst estimate, and should be read alongside the company’s own guidance once released.

Get Free Investment Predictions and Jubilant Pharmova Research at Univest

About Jubilant Pharmova

Jubilant Pharmova (NSE: JUBLPHARMA) operates in the industrials and capital goods space and is tracked on Univest under its NSE and BSE listings. Ahead of the Jubilant Pharmova Q1 Results FY27 print, the company’s Q4 FY26 base shows revenue of Rs.2,314 Cr and net profit of Rs.119 Cr, forming the base against which the Jubilant Pharmova Q1 Results FY27 estimates in this article are built. This Jubilant Pharmova Q1 Results FY27 snapshot is intended as a starting point for research, not a substitute for the company’s own disclosures.

Jubilant Pharmova Q1 FY27 Estimates

Metric	Q1 FY27E (Range)	Q1 FY26 Actual	YoY Growth
Revenue (Rs. Cr)	2,121-2,440	1,913	+19.2%
Net Profit / PAT (Rs. Cr)	71-91	102	-21.2%
Results Date	July-August 2026 (indicative)
12-Month Target (Uniresearch Estimate)	Rs.1,114-1,241

Univest, a SEBI-Registered Investment Advisor, Tracks Jubilant Pharmova Ahead of Q1 FY27 Results

Key Catalysts to Watch

1. Order Book Execution

Healthy order book execution translating into revenue recognition for the quarter is one of the primary variables that analysts are tracking ahead of Jubilant Pharmova’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Jubilant Pharmova share price target or faces renewed pressure.

2. Capex Revival in User Industries

Capex revival in core user industries supporting fresh order inflows is one of the primary variables that analysts are tracking ahead of Jubilant Pharmova’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Jubilant Pharmova share price target or faces renewed pressure.

3. Operating Leverage

Operating leverage on higher volumes aiding margin expansion versus last year is one of the primary variables that analysts are tracking ahead of Jubilant Pharmova’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Jubilant Pharmova share price target or faces renewed pressure.

Download the Univest iOS App or Univest Android App to track Jubilant Pharmova’s live price and Q1 FY27 result updates.

Key Risks to the Jubilant Pharmova Q1 Results FY27 Outlook

• Order execution delays pushing revenue recognition to later quarters.
• Raw material and input cost inflation pressuring margins.
• Slower capex recovery in key end-user industries affecting order inflows.

Q4 FY26 Performance Context for the Jubilant Pharmova Q1 Results FY27 Print

Jubilant Pharmova closed Q4 FY26 with revenue of Rs.2,314 Cr and net profit of Rs.119 Cr, a year-on-year revenue change of +19.2% and PAT change of -21.2%. This base underpins the Jubilant Pharmova Q1 Results FY27 projection used in this preview and should be read alongside the company’s own Jubilant Pharmova Q1 Results FY27 commentary once reported.

Technical Analysis Ahead of Jubilant Pharmova Q1 Results FY27

Jubilant Pharmova shares last traded at Rs.975. For the current 52-week high and low, support and resistance levels, investors should check the live chart on the Univest app or the NSE website, since these levels move intraday and are not reproduced here to avoid stale data.

Share Price Target Based on the Jubilant Pharmova Q1 Results FY27 Outlook

3-6 Month Target

Over a 3-6 month horizon, the Jubilant Pharmova Q1 Results FY27 trailing-growth framework points to a range of Rs.1,002-1,080 for Jubilant Pharmova, contingent on the Jubilant Pharmova Q1 Results FY27 print matching or beating the trailing growth trend.

12-Month Target

The 12-month target (Uniresearch estimate) tied to this Jubilant Pharmova Q1 Results FY27 view for Jubilant Pharmova works out to Rs.1,114-1,241, built on the same trailing revenue growth trend and current valuation multiple. Tracking with a constructive bias is how Univest research categorises the stock heading into Jubilant Pharmova Q1 Results FY27, not a formal Buy or Sell call.

FY27-28 Outlook

Looking out to FY27-28, a sustained continuation of the growth trajectory implied by this Jubilant Pharmova Q1 Results FY27 analysis would put Jubilant Pharmova in a Rs.1,246-1,422 range, though this is sensitive to sector-wide demand, cost trends and any change in the company’s competitive position.

What to Watch in the Jubilant Pharmova Q1 Results FY27 Print

• Revenue and PAT versus the Jubilant Pharmova Q1 Results FY27 estimate range in this preview.
• Management commentary on FY27 growth guidance and margin trajectory relevant to the Jubilant Pharmova Q1 Results FY27 narrative.
• Healthy order book execution translating into revenue recognition for the quarter
• Order execution delays pushing revenue recognition to later quarters

Conclusion on Jubilant Pharmova Q1 Results FY27

Jubilant Pharmova enters the Q1 FY27 results season trading at Rs.975, with the 12-month Uniresearch target range of Rs.1,114-1,241 reflecting a tracking with a constructive bias stance. Investors tracking the Jubilant Pharmova Q1 Results FY27 print should watch the catalysts and risks above and consult a SEBI-registered advisor before making investment decisions around the results.

FAQs on Jubilant Pharmova Q1 Results FY27

When are Jubilant Pharmova Q1 FY27 results expected?

Ans. Jubilant Pharmova’s Q1 FY27 results are expected in the July-August 2026 window, in line with the broader NSE and BSE results season for the quarter ending June 2026.

What is the Jubilant Pharmova Q1 FY27 revenue estimate?

Ans. The Uniresearch trailing-growth estimate for Jubilant Pharmova’s Q1 FY27 revenue is Rs.2,121-2,440 Cr, based on the Q1 FY26 base of Rs.1,913 Cr.

What is the Jubilant Pharmova share price target?

Ans. The 12-month Uniresearch estimate for Jubilant Pharmova share price target is Rs.1,114-1,241, based on trailing growth and current valuation multiples.

Is Jubilant Pharmova a good buy before Q1 FY27 results?

Ans. Jubilant Pharmova is tracking with a constructive bias heading into Q1 FY27 results. Investors should weigh the catalysts and risks in this article and consult a SEBI-registered advisor before investing.

What should investors watch in Jubilant Pharmova’s Q1 FY27 results?

Ans. Key items include revenue and PAT versus estimates, management commentary on FY27 guidance, and healthy order book execution translating into revenue recognition for the quarter.

Where can I track Jubilant Pharmova share price live?

Ans. Jubilant Pharmova share price can be tracked live on the Univest app and website, along with research updates from SEBI-registered analysts.